133 related articles for article (PubMed ID: 34328216)
21. Prostate Cancer Screening, Diagnostic, Treatment Procedures and Costs in Sub-Saharan Africa: A Situational Analysis.
Makau-Barasa LK; Manirakiza A; Carvalho AL; Rebbeck TR
Cancer Control; 2022; 29():10732748221084932. PubMed ID: 35350915
[TBL] [Abstract][Full Text] [Related]
22. A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease.
Ruseckaite R; Beckmann K; O'Callaghan M; Roder D; Moretti K; Millar J; Evans S
BMC Cancer; 2016 Aug; 16():607. PubMed ID: 27496055
[TBL] [Abstract][Full Text] [Related]
23. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
Dell'Oglio P; Bishr M; Boehm K; Trudeau V; Larcher A; Tian Z; Sosa J; Moschini M; Saad F; Capitanio U; Briganti A; Graefen M; Montorsi F; Karakiewicz PI
Eur Urol Focus; 2018 Dec; 4(6):834-841. PubMed ID: 28753853
[TBL] [Abstract][Full Text] [Related]
24. Potential New Approaches for Prostate Cancer Management in Resource-Limited Countries in Africa.
Bosland MC; Shittu OB; Ikpi EE; Akinloye O
Ann Glob Health; 2023; 89(1):14. PubMed ID: 36843668
[TBL] [Abstract][Full Text] [Related]
25. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL
Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
[TBL] [Abstract][Full Text] [Related]
26. Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
Fosså SD; Wiklund F; Klepp O; Angelsen A; Solberg A; Damber JE; Hoyer M; Widmark A;
Eur Urol; 2016 Oct; 70(4):684-691. PubMed ID: 27025586
[TBL] [Abstract][Full Text] [Related]
27. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
28. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
Sooriakumaran P; Nyberg T; Akre O; Widmark A; Hamdy F; Graefen M; Carlsson S; Steineck G; Wiklund NP
Eur Urol; 2017 Sep; 72(3):345-351. PubMed ID: 28416350
[TBL] [Abstract][Full Text] [Related]
29. Is Primary Androgen Deprivation Therapy a Suitable Option for Asian Patients With Prostate Cancer Compared With Radical Prostatectomy?
Ha US; Choi JB; Shim JI; Kang M; Park E; Kang S; Park J; Yang J; Choi I; Ahn J; Kwak C; Jeong CW; Kim CS; Byun SS; Seo SI; Lee HM; Lee SJ; Lee SH; Chung BH; Lee JY
J Natl Compr Canc Netw; 2019 May; 17(5):441-449. PubMed ID: 31085754
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer outcomes for men who present with symptoms at diagnosis.
Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
[TBL] [Abstract][Full Text] [Related]
31. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
[TBL] [Abstract][Full Text] [Related]
32. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
33. Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study.
Sengayi-Muchengeti M; Joko-Fru WY; Miranda-Filho A; Egue M; Akele-Akpo MT; N'da G; Mathewos A; Buziba N; Korir A; Manraj S; Lorenzoni C; Carrilho C; Hansen R; Finesse A; Somdyala NIM; Wabinga H; Chingonzoh T; Borok M; Chokunonga E; Liu B; Singh E; Kantelhardt EJ; Parkin DM
Int J Cancer; 2020 Dec; 147(11):3037-3048. PubMed ID: 32449157
[TBL] [Abstract][Full Text] [Related]
34. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
[TBL] [Abstract][Full Text] [Related]
35. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
[TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.
Garcia-Rodriguez J; Fernandez-Gomez JM; Cozar JM; Miñana B; Gomez-Veiga F; Rodriguez-Antolin A; ;
Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):156-163. PubMed ID: 32113829
[TBL] [Abstract][Full Text] [Related]
37. Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort.
Mezger NCS; Hämmerl L; Griesel M; Seraphin TP; Joko-Fru YW; Feuchtner J; Zietsman A; Péko JF; Tadesse F; Buziba NG; Wabinga H; Nyanchama M; Chokunonga E; Kéita M; N'da G; Lorenzoni CF; Akele-Akpo MT; Mezger JM; Binder M; Liu B; Bauer M; Henke O; Jemal A; Kantelhardt EJ
Oncologist; 2023 Nov; 28(11):e1017-e1030. PubMed ID: 37368350
[TBL] [Abstract][Full Text] [Related]
38. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
Sood A; Kishan AU; Evans CP; Feng FY; Morgan TM; Murphy DG; Padhani AR; Pinto P; Van der Poel HG; Tilki D; Briganti A; Abdollah F
Eur Urol Oncol; 2024 Feb; 7(1):27-43. PubMed ID: 37423774
[TBL] [Abstract][Full Text] [Related]
39. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
40. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
